Skip to main content

Table 2 New mutations detected in plasma ctDNA during treatment

From: Association of emergence of new mutations in circulating tumuor DNA during chemotherapy with clinical outcome in metastatic colorectal cancer

Patient ID

Time point

New mutation

cHGVS

pHGVS

Function

VAFs (%)

P06

Post-C2

KRAS

c.38G > A

p.G13D

missense

0.36

P07

Post-C4

CDK13

c.604_605insT

p.R202Lfs*68

frameshift

1.10

Post-C4

MTOR

c.617G > A

p.R206H

missense

0.73

P08

Post-C4

BRCA2

c.6232G > A

p.G2078R

missense

0.90

Post-C4

MYC

c.1211A > G

p.K404R

missense

0.32

Post-C4

FGFR2

c.269A > T

p.E90V

missense

0.56

Post-C4

EGFR

c.2327G > A

p.R776H

missense

0.25

P10

Post-C4

PIK3R2

c.451C > T

p.P151S

missense

1.23

Post-C4

DNMT3A

c.2077C > T

p.R693C

missense

0.57

Post-C4

NTRK1

c.1859G > A

p.C620Y

missense

0.60

Post-C4

MLL

c.10480A > G

p.N3494D

missense

0.60

  1. cHGVS Coding DNA reference sequences (Human Genome Variation Society), pHGVS Protein level amino acid sequences (Human Genome Variation Society), Post-C2 After 2 cycles of chemotherapy, Post-C4 After 4 cycles of chemotherapy